Naloxon B. Braun (Naloxone Hydrochloride)

Naloxone works by competitively binding to mu, kappa and delta opioid receptors, displacing opioid molecules that are causing depression of the central nervous system. This blockade stops the opioids from exerting their effects, allowing normal respiratory and neurological function to return quickly.

The specific dose of Naloxon B. Braun is determined by the prescribing clinician based on the patient’s condition, the opioid involved, and the route of administration. Healthcare providers follow local guidelines and clinical judgment to select the appropriate amount.

Safety data for naloxone in pregnancy and lactation are limited. It is generally considered when the benefits of treating a life‑threatening opioid overdose outweigh potential risks. Clinicians should evaluate each case individually and discuss any concerns with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Naloxon B. Braun contains naloxone, the most widely used opioid antagonist due to its rapid onset and short duration of action, making it ideal for emergency reversal. Alternatives such as nalmefene have longer half‑lives but are less commonly used in acute settings. Choice depends on clinical scenario and local protocols.

Naloxon B. Braun should be stored at controlled room temperature, below 25 °C, in its original packaging. Protect the product from direct light, moisture and extreme temperatures. Do not freeze the solution; inspect for particulate matter before use.

The product is supplied as a sterile injectable solution for intramuscular or intravenous injection. Administration is performed by trained medical personnel, typically using a pre‑filled syringe or vial, with dosage adjusted to the patient’s clinical needs.

Serious risks include severe hypertension, cardiac arrhythmias, pulmonary edema, seizures, and rare anaphylactic reactions. Immediate monitoring of cardiovascular status and respiratory function after administration is essential to detect and manage these events promptly.

Naloxon B. Braun is contraindicated in patients with known hypersensitivity to naloxone or any component of the formulation. Caution is advised in individuals with pre‑existing cardiovascular disease, as abrupt opioid reversal can cause rapid blood pressure changes.